Funding for this research was provided by:
Universität Zürich (Clinical research priority programme CRPP "Artifical Intelligence in oncological imaging")
Received: 22 April 2020
Accepted: 2 July 2020
First Online: 13 July 2020
Ethics approval and consent to participate
: The study protocol was approved by the local ethics committee (KEK-ZH-Nr. 2015-0171). As this study was of retrospective nature, a consent form was waived by the local ethics committee.
: Not applicable.
: M.H.: research grants and speaker’s fees from GE Healthcare. N.A.: advisory duties for AstraZeneca, Deniopharm. Speaker’s duty for AstraZeneca, Deniopharm, Brainlab, ViewRay. Research support by Brainlab, ViewRay. All other authors declare that they have no competing interests.